首页 › 基金 › Hosking Partners LLP › RPRX
Hosking Partners LLP 对 RPRX 的持仓历史
ROYALTY PHARMA PLC · 医疗保健
Hosking Partners LLP 在 Q3 2026 的 13F 申报中披露持有 RPRX(ROYALTY PHARMA PLC)489,935 股,市值约 US$28.6M,约占其申报组合的 1.02%,在其申报持仓中市值排名第 39 位。 Hosking Partners LLP 最近 5 个申报季度中有 5 个季度披露了 RPRX 持仓,最早可追溯至 Q3 2025。
最后更新: 2026-11-13 · 来源: SEC EDGAR Form 13F-HR
Hosking Partners LLP 对 RPRX 的持仓演变
Hosking Partners LLP 于 Q3 2025 首次披露 RPRX 持仓:170,604 股(约 US$6.0M)。 该持仓在 Q3 2026 达到峰值 489,935 股,市值约 US$28.6M。 在 5 次申报中,Hosking Partners LLP 2 次增持、1 次减持、1 次保持不变。 最近一期申报(Q3 2026)显示持股 489,935 股、市值约 US$28.6M。 持仓曾出现大幅变动:Q4 2025 增持约 91% (随后一个季度股价上涨 24%)、Q1 2026 增持约 53% (随后一个季度股价上涨 17%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2025 | 170.60K | $6.02M | 新进 |
| Q4 2025 | 326.05K | $12.60M | 增持 |
| Q1 2026 | 498.04K | $23.89M | 增持 |
| Q2 2026 | 488.11K | $27.37M | 减持 |
| Q3 2026 | 489.94K | $28.59M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 RPRX 与 13F 数据
RPRX(ROYALTY PHARMA PLC)属于医疗保健行业。我们追踪的基金中还有 48 只申报持有 RPRX,申报仓位最大的包括:Swedbank AB (US$598.8M), Baillie Gifford (US$534.1M), ROYAL LONDON ASSET MANAGEMENT LTD (US$348.6M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 RPRX 的基金
- Swedbank AB 10.26M 股 · $598.81M · Q3 2026
- Baillie Gifford 9.15M 股 · $534.11M · Q3 2026
- ROYAL LONDON ASSET MANAGEMENT LTD 5.97M 股 · $348.63M · Q3 2026
- Caledonia (Private) Investments Pty Ltd 5.78M 股 · $323.85M · Q2 2026
- Patient Capital Management, LLC 3.42M 股 · $199.71M · Q3 2026
- Dorsey Asset Management, LLC 2.46M 股 · $137.74M · Q2 2026
- Regal Partners Ltd 2.45M 股 · $137.25M · Q2 2026
- HOMESTEAD ADVISERS CORP 1.66M 股 · $96.68M · Q3 2026
- Clark Capital Management Group, Inc. 1.66M 股 · $93.24M · Q2 2026
- NEW SOUTH CAPITAL MANAGEMENT INC 1.45M 股 · $84.36M · Q3 2026
更多关于 Hosking Partners LLP
常见问题
How long has Hosking Partners LLP held RPRX?
Hosking Partners LLP has disclosed RPRX holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
What is Hosking Partners LLP's current position in RPRX?
As of Q3 2026, Hosking Partners LLP holds 489.94K shares of RPRX (ROYALTY PHARMA PLC), valued at $28.59M, representing 1.02% of its reported portfolio and ranking #39.
Has Hosking Partners LLP been buying or selling RPRX?
In the latest 13F filing (Q3 2026), Hosking Partners LLP held unchanged its position in RPRX. The position peaked in Q3 2026 at 489.94K shares.
Which other funds hold RPRX?
Other major institutional holders of RPRX include Swedbank AB, Baillie Gifford, ROYAL LONDON ASSET MANAGEMENT LTD, among 48 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.